Second interim analysis of clinical outcomes after 135 patients results in recommendation to continue remestemcel-l phase 3 trial in covid-19 ards

New york, nov. 11, 2020 (globe newswire) -- mesoblast limited (nasdaq: meso; asx: msb) today announced that the randomized controlled phase 3 trial of remestemcel-l in patients with moderate to severe acute respiratory distress syndrome (ards) due to covid-19 infection had received a recommendation to continue from the independent data safety monitoring board (dsmb) following completion of the trial's second interim analysis. the analysis was performed on the trial's first 135 patients, 45% of the total target of up to 300 randomized patients, with the dsmb recommending continuation after reviewing the trial's primary endpoint, all-cause mortality within 30 days of randomization and all safety data. the key secondary endpoint is days alive off mechanical ventilatory support within 60 days of randomization.
MESO Ratings Summary
MESO Quant Ranking